Founded in Shenzhen, China, HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The company integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation in both diseases.
Gwen Melincoff, Chief Business Advisor
Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, and product management. Ms. Melincoff previously served as Senior VP of Business Development at Shire Pharmaceuticals. She also served as board member of Tobira Therapeutics when it was acquired by Allergan.
Lawrence Goldkind, MD - Chief Medical Advisor
Former Deputy Director and Acting Division Director, Anti-inflammatory and Analgesic Drug Product of FDA CDER. Board-certified gastroenterologist and board-certified internist.
Carol Brosgart, MD
Dr. Brosgart is a Clinical Professor of Medicine in the Division of Global Health, Biostatistics and Epidemiology in the Department of Medicine at the University of California, San Francisco. She has held a number of senior management positions in the medical and biotechnology community including the Chief Medical Officer at Alios BioPharma (now J&J) and UCSF Benioff Children’s Hospital & Research Center. Dr. Brosgart also held a number of senior management positions at Gilead Sciences including Vice President, Public Health and Policy, Vice President, Medical Affairs, and Vice President, Clinical Research.
Stephen Harrison, MD
Medical Director for Pinnacle Clinical Research and President of Summit Clinical Research. Visiting Professor of Hepatology at Radcliffe Department of Medicine, University of Oxford. Past Associate Editor for Hepatology and currently Associate Editor for Alimentary Pharmacology and Therapeutics. Recently retired Colonel in the United States Army with 20 years of service, serving as the Gastroenterology Consultant to the Army Surgeon General. Board certified in both Internal Medicine and Gastroenterology.
Keith Lindor, MD
Former Dean of the Mayo Medical School and Chair in the Division of Gastroenterology and Hepatology. He also served as editor-in-chief of Hepatology and president of the American Association for the Study of Liver Diseases (AASLD) in 2016.
Santhi Swaroop Vege, MD
Professor of Medicine, Director of Pancreas Group, and a consultant in the Division of Gastroenterology at Mayo Clinic in Rochester, Minnesota.